Ethnomedicinal uses, phytochemistry, and pharmacology of the genus Sarcophyte: a review

Although medicinal plants have been used by ethnic communities since ancient times to prevent and treat various diseases, only a few have been scientifically documented. Therefore, due to their rare availability and lack of comprehensive scientific information, we reviewed the ethnomedicinal uses, phytochemistry, and pharmacological activities of plants within the genus Sarcophyte. To do this, we used specific search terms and phrases to retrieve relevant information from online sources published in English from 2000 to July 2023. The results showed that there are only two plants in the genus Sarcophyte (Sarcophyte sanguinea Sparrm. and Sarcophyte piriei Hutch.), which are traditionally used to treat a wide range of diseases, especially cancer, and skin, gastrointestinal, and urinogenital tract ailments in humans, and to cure animals in ethnoveterinary practices. It was noted that 13 secondary metabolites have been isolated from the two plants, the most prominent of which are flavonoids (diinsininol, diinsinin, and naringenin). The antioxidant activity of S. piriei is reported based on the scavenging of 2,2-diphenyl-1-picrylhydrazyl (DPPH) (IC50: 4.26 ± 0.22 μg/mL) and 2 -2′-Azino-di-[3-ethylbenzthiazoline sulfonate (ABTS) radicals (IC50: 4.62 ± 0.14 μg/mL), chelating iron (IC50: 1.82 ± 0.01 μg/mL, 3.50 ± 0.09 μg/mL), and nitric oxide (IC50: 9.97 ± 0.88 μg/mL, 9.09 ± 0.11 μg/mL). The methanolic stem extracts of S. piriei possess antimicrobial activity against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Vibrio fluvialis, and Enterococcus avium, with minimum inhibitory concentration (MIC) values ranging from 0.16 to 0.625 mg/mL, and a minimum bactericidal concentration (MBC) of 1.25 to 5 mg/mL. Cytotoxic effects of the extracts from the two plant species were also demonstrated. Sarcophyte piriei possesses therapeutic potential as evidenced by the inhibitory effects of the aqueous rhizome extract on edema (1,000 mg/kg) and prostaglandin synthesis (IC50 = 0.2 mg/mL). In addition, diinsininol and diinsinin were isolated from S. sanguinea inhibited prostaglandin synthesis (IC50: 9.20 µM, 13.14 µM) and platelet-activating factor-induced exocytosis. Therefore, based on this review, further scientific research is needed to demystify the links between traditional medicinal uses, various secondary metabolites, and the pharmacology of the two plants.

(IC 50 : 9.20 µM, 13.14 µM) and platelet-activating factor-induced exocytosis.Therefore, based on this review, further scientific research is needed to demystify the links between traditional medicinal uses, various secondary metabolites, and the pharmacology of the two plants.

KEYWORDS
anticancer, anti-inflammatory, antimicrobial, diinsinin, diinsininol, holoparasite, phytochemicals 1 Background The use of medicinal plants as therapeutic agents for human and animal diseases is an extensive and diverse phenomenon, demonstrating their beneficial role in meeting primary healthcare needs (Jamaddar et al., 2023).Moreover, medicinal plants play a significant role in the conventional healthcare system as they are a valuable source of various allopathic drugs currently used to treat diseases (Dey et al., 2021).Considering the high cost of conventional healthcare, especially in low-and middle-income countries (LIMCs), the higher efficacy in managing various diseases (Ekor, 2014;Patrício et al., 2022), and the cultural acceptability of botanical drugs, traditional medicine still plays an important role worldwide (Dey et al., 2021;Siddique et al., 2021;Ndhlovu et al., 2023).
The vast therapeutic potential of medicinal plants has attracted immense research interest from the scientific community to unearth alternative effective lead compounds for drug development, especially against devastating diseases (Abdalla and Mühling, 2019;Swamy, 2020;Salama et al., 2021).It is now well recognized that the pharmacological effects of medicinal plants are mediated by various bioactive secondary metabolites (Swamy, 2020).Consequently, research has demystified the pharmacological role of various phytochemicals in preventing, slowing down, or averting the pathogenesis of many diseases (Howes and Perry, 2011;Gaikwad et al., 2014;Howes, 2017;Ahmad et al., 2020;Moriasi et al., 2020a;Moriasi et al., 2021a).For instance, antioxidant-associated phytochemicals quench oxidative stress in the body, thereby preventing undesirable sequelae (Moriasi et al., 2020b).Amelioration of oxidative stress is key to preventing and reversing associated diseases such as diabetes mellitus, neurodegeneration, cancer, and metabolic syndrome, among others (Moriasi et al., 2020b;Moriasi et al., 2021b).Therefore, certain phytochemicals in medicinal plants can help predict the efficacy and potency of that plant against specific or a range of diseases.
The existence of traditional medicine depends primarily on the diversity of medicinal plants and the associated ethnomedicinal information on their preparation and use (Josephine Ozioma and Antoinette Nwamaka Chinwe, 2019).Thus, medicinal plants are an indispensable resource for maintaining the health and overall wellbeing of people and animals in various ethnic groups worldwide (WHO, 2013;Josephine Ozioma and Antoinette Nwamaka Chinwe, 2019;Okot et al., 2020).The popularity and high dependency on traditional medicine, especially in sub-Saharan Africa (James et al., 2018), denote its significant role in healthcare.However, rapidly increasing human populations, urbanization, climate change, and habitat destruction are harming essential medicinal plants and their resources (Okello and Kiringe, 2004;Kamau et al., 2016;Razgour et al., 2020).To address this, it is imperative to carefully investigate and document the ethnomedicinal information, pharmacological activities, and phytochemistry of promising plants to preserve the knowledge and facilitate further research aimed at valorizing their efficacy as potential sources of new drugs and to support conservation programs (Kamau et al., 2016;Kigen et al., 2014;Haque et al., 2022;Hmidouche et al., 2023).Accordingly, we reviewed the local and traditional medicinal uses, pharmacological activities, and phytochemistry of plants within the genus Sarcophyte because of the lack of comprehensive scientific information and because they are rarely encountered.
The Sarcophyte genus belongs to the plant family Balanophoraceae and the order Santalales (sandalwood), according to the Angiosperm Phylogeny Group IV classification system (Angiosperm Phylogeny Group, 2016;Nickrent, 2020).The family comprises 18 genera with over 100 species of root holoparasitic geophytes with a pantropical distribution (Dennis et al., 2023).The genus Sarcophyte comprises a single species of two plants: Sarcophyte sanguinea Sparrm.) and Sarcophyte piriei (Hutch.).The two plants are native to eastern and southern Africa, but they are rarely encountered due to their patchy distribution, leading to inadequate sampling, poor preservation, and insufficient research (Maroyi, 2017).
The two plants are used in traditional medicine to treat cancer, snake bites, and disorders of the respiratory, gastrointestinal, integumentary, reproductive, and nervous systems (Ogundaini et al., 1996;Muriuki, 2011;De Wet et al., 2013;Naidoo et al., 2013;Maroyi, 2017).However, there is a paucity of comprehensive scientific literature on the ethnomedicinal uses, phytochemistry, and pharmacological activities of plants of the genus Sarcophyte.Thus, sufficient scientific reports on the genus Sarcophyte are needed to help appraise its ethnomedicinal, pharmacological, and phytochemical value.
Therefore, this review provides a comprehensive account of the plants' ethnomedicinal uses, phytochemistry, and pharmacological activities of the two plants of the genus Sarcophyte.This review further highlights the existing research gaps and potential scientific opportunities that may significantly contribute to the valorization of the investigated plants as sources of alternative therapeutic agents for the treatment of various diseases.SCOPUS, SpringerLink, SciFinder, and Science Direct, using specific search terms and phrases such as "Sarcophyte," "Pharmacologic activity of Sarcophyte," "Taxonomy of Sarcophyte," "distribution/ diversity of Sarcophyte," "phytochemistry of Sarcophyte," and "ethnomedicinal uses of Sarcophyte."Additionally, an extensive search and analysis of traditional medicinal uses, phytochemistry, and pharmacological activities of plant species belonging to the genus Sarcophyte was performed using published articles, journals, Ph.D. and MSc.dissertations, conference papers, available data from herbaria, and books published in English.The materials were carefully screened, and only complete and relevant information was further evaluated and included in this review.Information on the worldwide distribution of plant species in the genus Sarcophyte was obtained from online databases, including JSTOR Global Plants (JGP) (JSTOR, 2022a), World Flora Online (WFO) (World Flora Database, 2022), Prelude Medicinal Plants (PMP) (Africamuseum, 2022), African Plant Database (APD) (APD, 2022), and Global Biodiversity Information Facility (GBIF) (GBIF, 2022).Species details recorded included collector, accepted name, species number, occurrence, and the herbarium.Species names were confirmed using the International Plant Name Index (IPNI) (IPNI, 2022) and the taxonomic data in the WFO database (IPNI, 2022).The PubChem database was used to verify the IUPAC names of secondary metabolites isolated from plants of the genus Sarcophyte, and their chemical structures were drawn using ChemBio Draw Ultra, version 14.0.

Botanical description
Plants of the Sarcophyte genus are characterized by their unique botanical features, as currently described in the World Flora Online (WFO) database (World Flora Online, 2022).Plants of this genus are perennial polyparasitic herbs that grow up to 40 cm long and attach themselves to the roots of various host plants, especially those of the Mimosaceae family.They form a large, warty, irregularly lobed tuber measuring 5-15 cm x 5-11 cm, and short stems surrounded by three to four lobed sheaths, 8-25 cm long.Some of the host plants for Sarcophyte include Acacia, Hyphaene spp., Commiphora spp., Ficus spp., Faidherbia albida (Delile) A. Chev., and Mimusops obtusifolia Lam.
Moreover, plants of the genus Sarcophyte possess numerous spirally arranged, scale-like, ovate-lanceolate leaves up to 3.5 cm long.Their inflorescence is fleshy, with a colored to bright red panicle measuring 5-10 cm in diameter, 2-6 cm long branches, and subtended by a bract.The bracts are ovate-lanceolate, measuring 0.8-2 cm x 0.5-1.2cm, and are only scaly at the base.The male inflorescence has many secondary flowering branches in groups of two to three, unisexual, usually regular, and 3 (-4)-merous.The pedicel is short, and the perianth segments are elliptic to oblong, measuring 1.5-3.5 mm x 1.5-2 m, with a blunt to acute apex, and flesh stamens measuring 1.5-2.5 mm.The female inflorescence has many secondary branches, each with 5-12 almost globular, spadixlike clusters, 0.4-1.4cm in diameter, with up to 200 flowers completely sunk in a common receptacle.They do not have a perianth, and their ovary is inferior and 3-celled, while the stigma is disc-shaped, the style reduced, and one-seeded.The fruits are pseudo-berry, aggregated in a rounded and reddish infructescence, with a fleshy epicarp, a hard endocarp, and crowded carpels of the separate flowers that are not consolidated as in a compound fruit (Schmelzer and Gurib-Fakim, 2013).The stamens of S. sanguinea are more than half of the perianth segments, and the flowers have a stinky, unpleasant odor, whereas the stamens of S. piriei are less than half the length of the perianth segments, and the flowers are odorless or have a fruity odor (Schmelzer and Gurib-Fakim, 2013).

Origin and geographic distribution
The genus Sarcophyte is native to Africa, and its distribution ranges from Ethiopia to South Africa (Wikimedia Foundation, 2022).Sarcophyte comprises a single species with only two plants, whose accepted names are S. sanguinea and S. piriei.Sarcophyte sanguinea is widespread in eastern and southern Africa, from Ethiopia and Somalia in the north and south to South Africa, while S. piriei is widespread in Zambia, Malawi, Mozambique, Zimbabwe, and East Africa, from Somalia and Ethiopia to Mozambique and Zimbabwe (Mduduzi and Aluwani, 2017).

Ethnomedicinal uses
This review observed that S. sanguinea is used ethnomedicinally to treat cervical cancer, pimples, dysentery, amenorrhea, swollen glands, gonorrhea, HIV/AIDS, genital warts, sores, shingles, hypertension, and vomiting in humans in various African ethnic communities (Table 1).In addition, it is used to treat black quarter disease and to control lice infestations in pigs (Table 1).
In addition, S. piriei is used to treat cancer, acne, skin sores, skin eruptions, burns, wounds, shingles, snakebites, sore throat, diarrhea, abdominal pain, menstrual pain, skin bruises, and toothache in traditional medicine (Table 1).The extensive application of these plants underscores their perceived therapeutic versatility in traditional medicine.However, the lack of quantitative data or prevalence rates for each application diminishes the accuracy of these claims.
This study also revealed that S. sanguinea has many diverse applications in South Africa, but only one use was reported in Malawi (Table 1).This regional divergence raises intriguing questions about the cultural, ecological, or historical factors influencing the use of the plant.Conversely, two uses were documented for S. piriei in Kenya, and only one was documented in South Africa, Somalia, and Tanzania (Table 1).The observed discrepancies in use reports necessitate a deeper exploration of the factors that contribute to these variations, such as cultural practices, ecological contexts, or methodological differences in ethnomedicinal and ethnobotanical data collection.
The identification of these secondary metabolites in S. piriei contributes valuable insights into the chemical composition of these plants and offers a foundation for further empirical exploration of their efficacy.Furthermore, the qualitative and quantitative analyses, along with the isolation and identification of specific compounds from these plants, provide a solid basis for future studies exploring the potential pharmacological and therapeutic applications of these secondary metabolites.

Pharmacological activities
The extracts and some of the isolated secondary metabolites from plants of the genus Sarcophyte possess biological activities, mainly in vitro antimicrobial and cytotoxic activities and in vivo anti-inflammatory activity (the only in vivo assay reported so far).
Previous studies show that plant extracts with high MIC values (>0.625 mg/mL) are ineffective in eradicating microbes (Mwitari et al., 2013;Clinical Laboratory Standards Institute CLSI, 2022).Therefore, this review reveals that the methanol stem extract of S. piriei is more effective against E. avium compared to the other microbial strains studied so far (Mwitari et al., Clinical Laboratory Standards Institute CLSI, 2022).Thus, there is a need to standardize the extracts before subjecting them to bioassays to demystify their efficacy: this will facilitate further antimicrobial investigations and lead to the isolation and optimization of lead molecules for drug development (Gakuya et al., 2020).However, Serratia marcescens has been reported to be resistant to the methanol and dichloromethane stem extracts of S. piriei, making them of no clinical significance (Mahammed et al., 2020;Mbakazi et al., 2022) The in vitro evaluation of the methanolic stem tuber extract of S. piriei using the lactate dehydrogenase (LDH) release assay demonstrated putative membrane-damage-induced cytotoxicity effects against Listeria ivanovii, E. avium, and E. coli, as indicated by the percentage of lactate dehydrogenase release (>50%) (Mbakazi et al., 2022).
Aqueous and methanol-dichloromethane stem extracts of S. sanguinea demonstrated lower antibacterial activities against Ureaplasma urealyticum, Oligella ureolytica, Gardnerella vaginalis, Trichomonas vaginalis, and Neisseria gonorrhoeae (MIC: 2.69 mg/ mL), indicating negligible antimicrobial efficacy (Naidoo et al., 2013) compared to the standard drug used (ciprofloxacin), whose mean MIC was lower (0.276 μg/mL) (Naidoo et al., 2013) based on microtiter plate dilution method.In addition, the plant extracts studied were inactive against Candida albicans (MIC>16 mg/mL), implying a lack of antifungal efficacy compared with amphotericin B (the reference standard), whose MIC was 2.5 μg/mL (Naidoo et al., 2013).Furthermore, an Ames test indicated that the methanol: dichloromethane (1:1) extract of S. sanguinea is mutagenic, while the aqueous extract is not mutagenic to the TA98 and TA100 strains of Salmonella typhimurium (1,000 and 200 colonies, respectively) when compared with the standard agent (sodium azide) tested on 500 colonies (Ramulondi, 2017).
Considering the variation in antimicrobial efficacy of extracts derived from these plants reported in the reviewed preliminary in vitro studies, there is a need to utilize comprehensive and standardized extraction and assay procedures to increase the reliability and reproducibility of the results (Pandey et al., 2014;Altemimi et al., 2017).In addition, these steps will provide a solid foundation for subsequent stages of drug development by systematically identifying lead molecules with therapeutic potential (Maina et al., 2023).Notably, careful attention to various factors, such as the selection of extraction solvents, extraction techniques, and quality control measures, is necessary to establish standardized procedures and optimize the antimicrobial efficacy of plant extracts (Wanjiru et al., 2022).
Furthermore, in-depth research is needed to unravel the specific mechanisms underlying the observed antibacterial and antiprotozoal activities of plant extracts derived from plants of the genus Sarcophyte.For instance, exploring the molecular and cellular interactions between bioactive secondary metabolites in target microorganisms will provide valuable insights into their mode of action and provide a solid basis for rational drug design and development (Abreu et al., 2012;Bor et al., 2016).Furthermore, it is crucial to determine the potential synergistic effects between different plant extracts and active secondary metabolites to uncover synergies that boost therapeutic efficacy and their potential applications in clinical practice (Abreu et al., 2012).
Elsewhere, extracts of S. sanguinea have been demonstrated to be non-toxic to brine shrimp larvae (LC 50 ˃ 2000 μg/mL) compared to potassium dichromate (the positive control agent), which was highly toxic to brine shrimp larvae at a concentration of 2 μg/mL, resulting in 100% mortality (Ramulondi, 2017).In vitro toxicity studies for conventional drugs and botanical drug interactions of the aqueous stem extract of S. sanguinea have shown to cause a 15% inhibition of β-glucuronidase at 10 μg/mL (Ramulondi, 2017), demonstrating its potential efficacy in inhibiting colonic genotoxicity, induced by deconjugation of drug and xenobiotic glucuronides in the gastrointestinal (GI) tract (Awolade et al., 2020).However, the same extract inhibits carboxylesterase by 38% and cytochrome P450 3A4 (CYP3A4) by 82% at a concentration of 10 μg/mL (Ramulondi, 2017), which may negatively impact xenobiotic metabolism in the GIT and liver (Sevrioukova and Poulos, 2013;Singh et al., 2021).
This review noted that the aqueous and dichloromethane: methanol extracts of S. sanguinea extracts possess in vitro antiproliferative activity against the human hepatocarcinoma cell line (HepG2/C3A), with approximately 69% cell death at a concentration of 100 μg/ml as compared to the positive control (melphalan), which revealed 100% cell death (Ramulondi, 2017).In addition, S. piriei extracts demonstrated lower in vitro antiproliferative activities against human colorectal carcinoma (Caco-2) and human hepatocellular carcinoma (HepG2) cells (CC 50 : 221 to >250 μg/mL) than the positive control drug (doxorubicin) (CC 50 = 2.27 μg/mL) (Mahmoud et al., 2011;Mbakazi et al., 2022).However, it is arguable that since various medicinal plants are often combined in traditional medicine to treat cancer, among other devastating conditions, the efficacy of these extracts may be improved when combined (Maina et al., 2023), or when another solvent, especially water, which is commonly used in traditional medicine, is used (Sri Widyawati et al., 2014;Truong et al., 2019).
Based on the reported findings, in-depth in vivo studies are necessary to substantiate and validate the observed effects of S. sanguinea extracts against cancer cells using different standardized experimental designs with appropriate animal models and controlled conditions to elucidate their pharmacokinetic and pharmacodynamic aspects in a physiological context.Research shows that the optimization of extraction methodologies represents a critical avenue for refining the therapeutic potential of plant extracts (Handa et al., 2008;Hamuel, 2012;Altemimi et al., 2017;Abubakar and Haque, 2020), such as those from S. sanguinea and S. piriei.This optimization process should consider different extraction solvents, temperature, duration, and pressure to attain maximum yields of the bioactive secondary metabolites while preserving their stability and bioavailability (Dai and Mumper, 2010;Pandey et al., 2014;Altemimi et al., 2017).The use of advanced techniques, such as chromatographic and spectroscopic analyses, can assist in characterizing and quantifying the extracted secondary metabolites, offering valuable insights into their pharmacological activities (Handa et al., 2008).
Moreover, exploring potential synergies with other medicinal plants may help to enhance the therapeutic efficacy of the investigated plant extracts by improving their pharmacokinetics and spectrum of therapeutic effects, as reported in previous studies (Zhang et al., 2019;Ndung et al., 2018;Karki et al., 2021;Jouda, 2013).Systematic screening of compatible plant combinations, guided by traditional knowledge and modern pharmacological principles, would be critical in identifying synergistic relationships that amplify the therapeutic benefits of the more promising extracts.
In addition, traditional knowledge systems often incorporate specific solvents, and investigating the implications of such choices on the extraction of bioactive secondary metabolites can offer valuable insights into the efficacy of these preparations in treating the conditions claimed (Do et al., 2014).Thus, collaborative efforts involving traditional practitioners and modern scientists can bridge the gap between empirical knowledge and scientific validation, facilitating a holistic understanding of the therapeutic potential inherent in traditional practices.

Anti-inflammatory activity
Recent in vivo studies have shown that the aqueous rhizome extract of S. piriei significantly inhibited 50% of carrageenaninduced edema in rodents at a dose of 1,000 mg/kg after 10 h (Ogundaini et al., 1996).In addition, this extract effectively inhibited in vitro prostaglandin synthesis (IC 50 = 0.2 mg/mL) comparable to aspirin, suggesting its anti-inflammatory efficacy (Ogundaini et al., 1996).Moreover, diinsininol and diinsinin, isolated from the tuber/rhizome of S. sanguinea, inhibit in vitro prostaglandin synthesis with IC 50 values of 9.20 and 13.14 µM, respectively, and platelet-activating factor-induced exocytosis with IC 50 values of 49 and 39 μM, respectively (Ogundaini et al., 1996;Attiq et al., 2018).
This review highlights the promising anti-inflammatory properties exhibited by the aqueous rhizome extracts of S. sanguinea and S. piriei, which are mainly attributed to diinsininol and diinsinin.While these findings hold potential for therapeutic applications, a successful translation into clinical practice necessitates a comprehensive approach that includes rigorous pre-clinical investigations, an intricate understanding of pharmacokinetics and pharmacodynamics, and robust clinical trials to establish safety and efficacy in human subjects (Shakya, 2016;Jamshidi-Kia et al., 2018).
Extensive pre-clinical studies are essential to elucidate the safety profile and efficacy in various animal models to ensure reproducibility and consistency of the observed antiinflammatory effects and to provide a solid foundation for subsequent clinical exploration (Nasri and Shirzad, 2013;Moriasi et al., 2021b).In addition, a nuanced understanding of the pharmacokinetic and pharmacodynamic characteristics of diinsininol and diinsinin, including absorption, distribution, metabolism, and excretion within the biological system, is imperative (Raj and Raveendran, 2019).Furthermore, determining the optimal dosage and route of administration and assessing potential side effects and drug interactions are crucial to determining their safety profile and maximizing their therapeutic benefit (Turner et al., 2011;Kathare et al., 2021).
In addition, well-designed clinical trials involving human subjects are indispensable to validating the anti-inflammatory effects observed in pre-clinical studies.These trials should rigorously adhere to ethical standards, involve diverse participant populations to ensure broader applicability, and employ robust methodologies to yield reliable and generalizable results (Knowles, 2014).The amalgamation of these scientific endeavors is integral to the successful translation of the anti-inflammatory properties of the aqueous rhizome extracts of S. sanguinea and S. piriei and their constituent secondary metabolites into clinically effective therapeutic interventions.

Limitations
Our review, although comprehensive, has some limitations.The few reviewed materials may not adequately provide sufficient information on the local and traditional medicinal uses and the pharmacology and phytochemistry of the explored plants.In addition, we did not independently verify the efficacy reported in the reviewed literature; therefore, we could not offer specific applications in clinical practice.Moreover, we observed that only preliminary studies were performed involving in vitro models; therefore, they may not mirror in vivo effects, the reports of which are currently unavailable.

Conclusion and future directions
This study summarizes for the first time the traditional uses, phytochemistry, and pharmacology of plants of the genus Sarcophyte.This review noted that extracts of these plants have wide traditional medicinal applications, ranging from the treatment of infectious diseases, disorders of the skin, gastrointestinal and urogenital tracts, and cancer, among others.Also, their extracts possess various in vitro cytotoxic effects against normal cell lines, cancer cell lines, brine shrimp nauplii, and some microbes.In addition, the extracts of these plants possess considerable antioxidant and antiinflammatory activities.In particular, the available literature revealed that only the anti-inflammatory activity of the pure isolated secondary metabolites had been performed, leaving a significant lack of information on other bioactivities, including those of the other phytochemicals, which should be explored empirically.
Based on the current review, we recommend further empirical investigations to evaluate the toxic effects and pharmacological activities of the extracts and isolated secondary metabolites using a bio-assay-guided approach to decipher their potential.In addition, bioactivity-guided fractionation, identification, and characterization of the secondary metabolites, mainly against pathogenic microbes, oxidative stress, inflammation, and cancer, among others, should be conducted based on the documented ethnomedicinal claims.

TABLE 1
Traditional medicinal uses of and preparation of plants of the genus Sarcophyte.